Sickle cell disease has stumped researchers for years. Now, gene therapy breakthroughs are changing the game. This condition affects about 100,000 people in the U.S., mainly African American and Hispanic American communities1.
The FDA has given the green light to two new gene therapies: Casgevy and Lyfgenia. These treatments mark a big step forward for sickle cell anemia patients1.
Casgevy is the first FDA-approved treatment using CRISPR/Cas9 genome editing. It showed amazing results in clinical trials1.
93.5% of patients were free from severe pain crises for at least a year. These new therapies offer fresh hope for those battling this tough genetic condition2.
Key Takeaways
- Two major gene therapy treatments recently approved by FDA
- Casgevy uses innovative CRISPR/Cas9 genome editing technology
- 93.5% success rate in clinical trials for reducing severe pain crises
- Breakthrough treatments offer new hope for sickle cell patients
- Significant impact on African American and Hispanic American communities
Understanding Sickle Cell Disease
Sickle cell disease is a complex genetic blood disorder. It impacts thousands of lives worldwide. Your understanding can make a difference in recognizing its challenges and treatments.
What is Sickle Cell Disease?
Sickle cell disease is an inherited blood disorder. It’s characterized by abnormal hemoglobin production. The genetic treatment focuses on addressing the mutation that causes misshapen red blood cells3.
These sickle-shaped cells can block blood flow. This leads to painful complications and potential organ damage.
Symptoms and Complications
Patients experience various challenging symptoms, including:
- Intense pain crises
- Increased risk of infections
- Potential organ damage
- Reduced oxygen delivery
Sickle cell anemia gene therapy offers hope for managing these medical challenges4. It may be recommended for those 12 and older with repeated pain events4.
Diagnosis and Management
Diagnosing sickle cell disease involves genetic testing and blood analysis. Current management strategies include:
- Regular medical monitoring
- Pain management techniques
- Potential blood transfusions3
Modern medical advances are transforming how we approach this challenging genetic condition.
The FDA has approved two groundbreaking cell-based gene therapies. Casgevy and Lyfgenia are for sickle cell patients 12 years and older3.
These innovations represent a significant breakthrough in genetic treatment. They offer new hope for those living with sickle cell disease.
The Science Behind Gene Therapy
Gene therapy is a groundbreaking approach to treating genetic disorders. It offers hope for patients with complex medical conditions. This innovative method has revolutionized medical research, especially for challenging diseases like sickle cell.
What is Gene Therapy?
Gene therapy modifies a patient’s genetic material to treat or prevent disease. For sickle cell patients, it targets the specific genetic mutation causing the disease5.
Sickle cell disease affects over 100,000 people in the United States. Worldwide, several million individuals live with this condition5.
Historical Overview of Gene Therapy
Gene therapy’s journey has seen significant milestones. Scientists have developed sophisticated techniques to address genetic challenges.
Researchers have made remarkable progress in modifying genetic material. Their work aims to improve patient outcomes, especially for blood-related disorders.
- Early experimental approaches
- Development of vector systems
- Advanced genetic modification techniques
Mechanisms of Action in Sickle Cell Disease
Sickle cell gene therapy targets the disease’s root cause at the genetic level. Researchers have developed advanced approaches to modify blood-forming stem cells5:
- Gene addition through vector systems
- Gene editing using precise genomic modifications
The ultimate goal is to create a sustainable solution that provides patients with healthy, non-sickle red blood cells.
Lentiviral vectors have shown promising results in human β-globin expression. These vectors have produced significant levels among erythroid progeny5.
More than 80% of potential transplant candidates lack a matched sibling donor. This fact makes these innovative approaches critical for treatment5.
| Approach | Key Characteristics | Potential Impact |
|---|---|---|
| Gene Addition | Transferring functional genes | Corrects genetic defect |
| Gene Editing | Direct genomic modifications | Permanent genetic corrections |
Gene therapy’s potential benefits continue to expand. It offers new hope for patients with genetic disorders. These innovative approaches promise to transform sickle cell disease treatment strategies6.
Recent Breakthroughs in Gene Therapy
Cutting-edge genetic solutions for sickle cell anemia are evolving rapidly. New hope emerges for patients worldwide. Groundbreaking research is transforming gene editing approaches, with remarkable clinical trial results7.
Key Clinical Trials Revolutionizing Treatment
The RUBY Trial marks a pivotal moment in sickle cell disease research. This multicenter clinical trial shows extraordinary potential for gene therapy.
- 18 patients underwent experimental gene editing cell therapy7
- All patients remained free of painful disease events7
- Patients followed for five months showed complete anemia resolution7
Innovative Research Achievements
Researchers have made big strides in understanding sickle cell disease. In the US, about 100,000 individuals live with this challenging condition8.
The African American community is heavily affected. One in 365 babies are born with the disease7.
“These breakthrough therapies represent a new era of hope for patients struggling with sickle cell disease.”
Emerging Therapeutic Approaches
Two groundbreaking therapies got FDA approval in 2023: CASGEVY and LYFGENIA. These treatments offer new ways to manage sickle cell disease.
They use gene therapy to change patients’ cells. This helps produce healthy red blood cells9.
The future of gene editing for sickle cell anemia looks bright. Research institutions are developing more advanced genetic solutions. These could greatly improve patient outcomes.
Prominent Gene Therapy Treatments for Sickle Cell Disease
Gene therapy brings new hope for sickle cell disease patients. These innovative treatments are changing how we tackle this complex genetic disorder. They offer potential cures that were once unthinkable.
LentiGlobin: Breakthrough Genetic Modification
LentiGlobin is a game-changer in gene therapy. It uses lentiviral vector technology to modify patients’ blood stem cells10.
The process involves three main steps. First, doctors extract the patient’s stem cells. Then, they genetically modify these cells. Finally, they put the corrected cells back into the patient.
- Extracting patient’s own stem cells
- Genetically modifying these cells
- Reinfusing the corrected cells back into the patient
CRISPR-Cas9: Precision Gene Editing
CRISPR-Cas9 has transformed genetic treatments for sickle cell disease. The Innovative Genomics Institute developed this precise gene-editing approach11.
This method targets specific genetic mutations. It helps produce healthy hemoglobin. As a result, it may eliminate disease symptoms altogether.
- Targeting specific genetic mutations
- Producing healthy hemoglobin
- Potentially eliminating disease symptoms
Emerging Therapies
Scientists are working on new promising therapies. They’re exploring creative strategies to combat sickle cell disease.
| Therapy Type | Key Approach | Potential Impact |
|---|---|---|
| β-globin Strategy | Modify beta-globin gene | Improve hemoglobin production |
| γ-globin Strategy | Increase fetal hemoglobin | Reduce sickling effects |
“Gene therapy offers a glimpse of hope for sickle cell patients, potentially transforming lives through cutting-edge genetic interventions.” – Research Expert
These new gene therapy techniques are pushing medical science forward. They’re opening doors for sickle cell patients that were once closed12.
How Gene Therapy Works for Sickle Cell Patients
Gene therapy targets the root cause of sickle cell disease. It addresses the genetic mutation responsible for the condition. This innovative treatment offers hope for long-term relief to patients13.
Targeting the Genetic Mutation
The treatment corrects the underlying genetic defect in sickle cell disease. Researchers modify patients’ stem cells to produce healthy hemoglobin. Two FDA-approved therapies, CASGEVY™ and LYFGENIA™, have emerged as significant breakthroughs14.
- Editing DNA within patient cells
- Modifying stem cell genetic structure
- Restoring normal hemoglobin production
Repairing Hemoglobin Production
Gene therapy aims to boost healthy hemoglobin levels in patients. A 20% level of healthy hemoglobin can significantly improve symptoms13.
Clinical trials have shown impressive results. Some treatments have eliminated painful crises in over 90% of patients14.
| Treatment | Key Outcome |
|---|---|
| CASGEVY™ | Eliminated painful crises in 90% of patients |
| LYFGENIA™ | Produces non-sickling hemoglobin |
The Role of Stem Cells
Stem cells are crucial in gene therapy for sickle cell disease. Doctors extract and modify a patient’s stem cells. They then reintroduce these cells to the body15.
“Gene therapy offers a potential cure by transforming a patient’s own cells into a powerful healing mechanism.”
The treatment is promising but complex and expensive. About 60 patients have started the genetic treatment process. Costs range between $2.2 million and $3.1 million per patient15.
The Promise of Gene Editing Technologies
Gene editing is a groundbreaking frontier in medical science. It offers cutting-edge genetic solutions for complex disorders like sickle cell disease. These innovative approaches are revolutionizing our understanding and treatment of genetic conditions16.
Overview of CRISPR Technology
CRISPR technology has emerged as a powerful tool in genetic research. It allows scientists to make targeted modifications to DNA sequences. This precision technique can potentially correct genetic mutations17.
CRISPR works like a molecular scissor. It can cut, remove, or replace specific genetic segments with remarkable accuracy.
- Precise genetic modification
- Targeted DNA editing
- Potential for disease correction
Advancements in Precision Medicine
Precision medicine is transforming healthcare by tailoring treatments to individual genetic profiles. For sickle cell patients, this means potentially permanent solutions. These solutions address the root genetic cause of the disease18.
Gene-editing technologies offer hope for personalized treatments. These treatments could dramatically improve patient outcomes.
| Gene Editing Technology | Potential Impact |
|---|---|
| CRISPR/Cas9 | Direct genetic mutation correction |
| Base Editors | Precise point mutation correction |
| Lentiviral Vector Delivery | Gene therapy introduction |
Pros and Cons of Gene Editing
Gene editing presents incredible opportunities, but it also comes with challenges. The potential to permanently modify disease-causing genes must be balanced with careful scientific scrutiny.
Researchers continue to explore the long-term implications of these innovative approaches. They also focus on ensuring the safety of sickle cell gene therapy techniques.
“Gene editing is not just about changing DNA, but about changing lives.” – Genetic Research Expert
Gene editing technologies inspire hope for patients with genetic disorders. They promise a future where personalized genetic treatments become a reality17.
Patient Stories and Testimonials
Gene therapy has revolutionized sickle cell anemia treatment. It offers hope to patients battling this challenging genetic disorder. These patient journeys inspire millions affected by this condition19.
Inspiring Success Tales
Gene therapy’s benefits shine through remarkable patient experiences. At least 45 sickle cell patients have received groundbreaking gene-editing treatments. Many have shown positive outcomes20.
Kendric Cromer, a 12-year-old pioneer, was the first to receive this treatment. He spent 44 days in the hospital pursuing a chance at a normal life19.
The Emotional Journey of Patients
Patients face complex emotional challenges during gene therapy. The treatment process involves intricate procedures, including:
- Extensive medical consultations
- Comprehensive genetic testing
- Emotional support and counseling
- Lengthy hospital stays
Long-term Effects on Quality of Life
Gene therapy’s impact extends beyond immediate treatment. Over 90% of treated individuals become pain-free, dramatically improving their lives21.
Doctors will monitor patients for 15 years. This will assess the long-term effectiveness and safety of this groundbreaking approach20.
“Gene therapy offers more than a treatment – it offers a second chance at life,” says Dr. Michael Roberts, lead researcher in sickle cell gene therapy.
| Treatment Metric | Patient Outcomes |
|---|---|
| Pain-Free Patients | Over 90% |
| Monitoring Duration | 15 Years |
| FDA Approved Therapies | 2 (CASGEVY™ and LYFGENIA™) |
Approximately 100,000 people in the United States have sickle cell disease. These breakthroughs represent a huge leap forward in medical science19.
Challenges and Limitations of Gene Therapy
Gene therapy for sickle cell disease offers hope. It faces significant hurdles that need careful consideration. Understanding these obstacles is key to developing better treatments.
Potential Risks and Side Effects
Gene therapy for sickle cell disease involves complex procedures. Patients may experience side effects from conditioning chemotherapy22. Insertional oncogenesis remains a concern with certain vector systems23.
- Risk of cancer development
- Potential immune system complications
- Long-term health uncertainties
Regulatory Hurdles
Regulatory agencies demand extensive safety and efficacy evidence. Gene therapy’s complex nature requires rigorous testing. Long-term monitoring is essential for approval23.
Accessibility and Affordability Concerns
Gene therapy costs are steep. Treatment ranges from $500,000 to $700,000 over several years22. This price tag makes it inaccessible for many patients.
Underserved communities face particular challenges in accessing this treatment23.
| Challenge | Impact |
|---|---|
| Treatment Cost | $500,000 – $700,000 |
| Donor Availability | Less than 20% have appropriate donors |
| Patient Understanding | 15-18% struggle with comprehending treatment details |
“The promise of gene therapy is transformative, but we must address its current limitations to make it a realistic option for all patients.” – Medical Research Expert
Optimism about gene therapy as a cure remains strong22. Ongoing research and innovation are crucial to overcoming current limitations.
Future Trends in Gene Therapy for Sickle Cell Disease
Revolutionary treatments for sickle cell disease are evolving rapidly. Cutting-edge research is transforming how we approach this genetic disorder. Hope is growing for patients worldwide24.
Potential New Treatments on the Horizon
Emerging therapies show remarkable promise for sickle cell patients. Innovative gene editing approaches are tackling the disease’s genetic root25.
- CRISPR-based treatments targeting genetic mutations
- Advanced stem cell manipulation techniques
- Personalized genetic intervention strategies
Research Directions and Innovations
Scientists are exploring new paths to combat sickle cell disease. Recent breakthroughs have been exciting.
- Base editing techniques to modify hemoglobin production25
- Bacteriophage-CRISPR hybrid approaches25
- Precision genetic repair mechanisms
“The future of sickle cell treatment lies in our ability to precisely edit genetic code” – Leading Genetic Researcher
The Role of Personalized Medicine
Personalized medicine is changing sickle cell treatment. Doctors can now tailor therapies to individual genetic profiles. This leads to more effective interventions26.
Advanced gene therapies can cost $2-3 million per patient. This shows the significant investment in these groundbreaking treatments26.
Your genetic blueprint could unlock revolutionary treatments for sickle cell disease. Ongoing research promises better outcomes through genetic interventions24.
Collaborations and Partnerships in Research
Strategic partnerships are revolutionizing sickle cell gene therapy. Academic institutions and industry leaders are teaming up. These alliances are driving innovative genetic solutions for patients worldwide27.
Research partnerships are speeding up gene therapy treatments. The NIH and Gates Foundation are investing heavily in medical breakthroughs. They’re each putting $100 million towards gene-based treatments for sickle cell disease and HIV2728.
Key Research Collaboration Highlights
- NIH and Gates Foundation partnership aims to advance gene therapy clinical trials27
- Focus on developing globally accessible treatments28
- Targeting research in the United States and sub-Saharan Africa2728
Impactful Partnership Outcomes
These collaborations have produced impressive results. Six gene therapy products have been approved since 2016. Over 800 cell and gene-based therapies are in clinical development27.
| Research Focus | Investment | Target Region |
|---|---|---|
| Sickle Cell Disease | $100 Million | United States & Africa |
| HIV Treatment | $100 Million | Global Health Settings |
“Collaborative research is the key to unlocking innovative treatments for genetic diseases.” – Research Leadership, NIH
These partnerships blend academic know-how with industry resources. They’re pushing the limits of sickle cell gene therapy. The aim is to create genetic solutions that transform patient care28.
These efforts bring hope to millions affected by genetic disorders. Cutting-edge treatments are now within reach. The future of gene therapy looks brighter than ever.
Healthcare Access and Education
Gene therapy for sickle cell disease is a groundbreaking medical advancement. It demands thorough patient education and robust healthcare support. Understanding genetic treatment helps patients make informed health decisions.
Importance of Patient Education
Educating patients about genetic treatment for sickle cell disease is vital. Over 90% of those affected live in low- and middle-income countries. This underscores the need for accessible medical information29.
Patients must grasp treatment options, potential outcomes, and risk factors. They should also understand possible complications and long-term management strategies.
- Treatment options and potential outcomes
- Risk factors and potential complications
- Long-term management strategies
Resources for Patients and Families
Comprehensive resources can greatly enhance patient experiences with gene therapy. Key support mechanisms include genetic counseling services, patient support groups, and financial assistance programs.
- Genetic counseling services
- Patient support groups
- Financial assistance programs
“Knowledge is the first step towards effective treatment and management of sickle cell disease.”
Advocating for Policy Changes
Recent FDA approvals highlight the need for continued advocacy. Two cell-based gene therapies were approved in December 2023. These treatments are estimated to cost between $2.2 and $3.1 million30.
Patients and advocates must push for improved insurance coverage and increased research funding. They should also work to ensure treatment availability for all patients.
| Policy Focus Areas | Key Objectives |
|---|---|
| Insurance Coverage | Reduce financial barriers |
| Research Funding | Support continued medical innovations |
| Access Equity | Ensure treatment availability for all patients |
Your active participation can drive meaningful change in sickle cell disease treatment and support.
Conclusion: The Future of Gene Therapy for Sickle Cell Disease
Gene Therapy for Sickle Cell Disease offers new hope for thousands of patients. Recent breakthroughs have led to revolutionary treatments. These advancements are changing how we manage this condition31.
Cutting-edge therapies like Casgevy and Lyfgenia show great promise. They tackle the genetic roots of sickle cell disease31. The National Heart, Lung and Blood Institute invests $90 million yearly in vital research32.
The outlook is bright. Experts predict 66 new gene therapies by 203231. Scientists are working hard to improve patient outcomes. Your support can speed up research progress.
Summary of Key Points
Major strides include new gene therapies and increased funding. Our grasp of genetic treatments is growing. These advances could greatly improve patients’ lives.
Hope for Sickle Cell Patients
Every scientific step forward brings fresh hope. New treatments promise to be more effective and less invasive. These options could transform life for those with sickle cell disease.
A Call to Action for Support and Research
Your involvement can make a difference. Support research and raise awareness. Advocate for ongoing medical innovation. Together, we can reshape sickle cell disease treatment.
FAQ
What is sickle cell disease?
Sickle cell disease is an inherited blood disorder. It’s caused by a genetic mutation in hemoglobin. This mutation leads to abnormally shaped red blood cells that can restrict blood flow.
These cells can cause severe pain and organ damage. The disease affects about 100,000 people in the U.S. It’s most common among African Americans and Hispanic Americans.
How does gene therapy work for sickle cell disease?
Gene therapy modifies a patient’s blood-forming stem cells. It aims to correct the genetic mutation. Two main approaches are used: gene addition and gene editing.
The goal is to produce normal hemoglobin or hemoglobin with antisickling properties. This provides a lifelong supply of healthy red blood cells.
What recent breakthroughs have occurred in sickle cell gene therapy?
The FDA approved two milestone treatments: Casgevy and Lyfgenia. These are for patients 12 years and older. Casgevy is the first FDA-approved therapy using CRISPR/Cas9 genome editing technology.
These treatments are one-time, single-dose infusions. They modify patients’ own blood stem cells to correct the sickle cell mutation.
What are the potential benefits of gene therapy for sickle cell patients?
Clinical trials have shown promising results. Patients remained free of painful sickle cell events and resolved anemia. The therapy offers hope for a potential long-term solution.
It could improve patients’ quality of life. It may also reduce the frequency of painful crises.
Are there any risks associated with gene therapy for sickle cell disease?
Gene therapy does come with potential risks. These include side effects from conditioning chemotherapy. There’s also a risk of insertional oncogenesis with some vector systems.
Long-term safety studies are still needed. Researchers are working to minimize these risks and improve treatment safety.
How accessible is gene therapy for sickle cell disease?
Currently, gene therapy has accessibility challenges. The treatments require specialized facilities and expert medical teams. They’re likely to be expensive.
Researchers and advocates are working to improve access. Future developments may make the treatment more widely available.
What technologies are being used in gene therapy for sickle cell disease?
Two primary gene editing technologies are used: CRISPR/Cas9 and CRISPR/Cas12a. These advanced tools allow for precise genome editing. They can remove, add, or replace DNA sequences.
Researchers are continually refining these technologies. They aim to improve their effectiveness and safety.
Source Links
- FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease – https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease
- Gene therapy for sickle cell disease: moving from the bench to the bedside – https://pmc.ncbi.nlm.nih.gov/articles/PMC9069474/
- Sickle Cell Disease | ASGCT – https://patienteducation.asgct.org/disease-treatments/sickle-cell-disease
- Gene Therapy for Sickle Cell Disease – https://www.dukehealth.org/treatments/gene-therapy-sickle-cell-disease
- Gene Therapy for Sickle Cell Disease: An Update – https://pmc.ncbi.nlm.nih.gov/articles/PMC6123269/
- New gene therapy for sickle cell disease has been a long time coming, but is it a complete game-changer? – https://www.uclahealth.org/news/article/new-gene-therapy-sickle-cell-disease-has-been-long-time
- Novel Gene Therapy for Sickle Cell Shows Positive Results – https://newsroom.clevelandclinic.org/2024/06/14/novel-gene-editing-therapy-continues-to-show-positive-results-in-sickle-cell-patients
- Advances in Sickle Cell Disease: New Gene Therapies and Management Strategies – https://www.pharmacytimes.com/view/advances-in-sickle-cell-disease-new-gene-therapies-and-management-strategies
- Frontiers | Recent advancements in gene therapy for sickle cell disease and β-thalassemia – https://www.frontiersin.org/journals/hematology/articles/10.3389/frhem.2024.1468952/full
- UChicago Medicine among the first in the country to offer newly approved sickle cell gene therapies – UChicago Medicine – https://www.uchicagomedicine.org/forefront/pediatrics-articles/2024/january/comer-offers-new-gene-therapy-for-sickle-cell-patients
- Novel Gene Therapy Trial for Sickle Cell Disease Launches – https://www.ucsf.edu/news/2024/11/428941/novel-gene-therapy-trial-sickle-cell-disease-launches
- Gene Therapy for Sickle Cell Disease – https://www.chop.edu/gene-therapy-sickle-cell-disease
- Can gene therapy help treat sickle cell? – https://www.medicalnewstoday.com/articles/sickle-cell-therapy
- FDA Approves Two Gene Therapies for Sickle Cell Disease – https://www.chop.edu/news/fda-approves-two-gene-therapies-sickle-cell-disease
- Sickle cell gene therapies roll out slowly – https://www.npr.org/sections/shots-health-news/2024/09/19/nx-s1-4978692/sickle-cell-gene-therapies
- Gene editing holds the promise of a sickle cell cure – https://www.stjude.org/research/progress/2023/gene-editing-holds-promise-of-sickle-cell-cure.html
- CRISPR/Cas9 gene editing for curing sickle cell disease – https://pmc.ncbi.nlm.nih.gov/articles/PMC8049447/
- The promise of gene therapies – https://corporate.thermofisher.com/content/tfcorpsite/us/en/index/about/leadership/the-promise-of-gene-therapies.html
- Life Without Sickle Cell Beckons Boy Who Completed Gene Therapy – https://www.nytimes.com/2024/10/21/health/sickle-cell-disease-gene-therapy-patient.html
- First sickle cell patient treated with CRISPR gene-editing still thriving – https://www.npr.org/sections/health-shots/2021/12/31/1067400512/first-sickle-cell-patient-treated-with-crispr-gene-editing-still-thriving
- Gene Therapy for Sickle Cell Disease: Marie-Chantal’s Story – https://www.chop.edu/stories/gene-therapy-sickle-cell-disease-marie-chantal-s-story
- Gene Therapy for Sickle Cell: Looking for a Disease Cure – https://www.verywellhealth.com/gene-therapy-for-sickle-cell-disease-4588187
- The challenge of eliciting opinions of gene therapy for SCD – https://pmc.ncbi.nlm.nih.gov/articles/PMC10726235/
- Recent Advances in the Treatment of Sickle Cell Disease – https://pmc.ncbi.nlm.nih.gov/articles/PMC7252227/
- CRISPR Clinical Trials: A 2024 Update – https://innovativegenomics.org/news/crispr-clinical-trials-2024/
- Advances in Sickle Cell Disease – https://www.physiology.org/publications/news/the-physiologist-magazine/2024/may/advances-in-sickle-cell-disease
- Backgrounder: NIH Collaboration on Gene-Based Cures for SCD and HIV – https://www.nih.gov/news-events/news-releases/backgrounder-nih-collaboration-gene-based-cures-scd-hiv
- NIH launches new collaboration to develop gene-based cures for sickle cell disease and HIV on global scale – https://www.nih.gov/news-events/news-releases/nih-launches-new-collaboration-develop-gene-based-cures-sickle-cell-disease-hiv-global-scale
- Strategies to increase access to basic sickle cell disease care in low- and middle-income countries – https://pmc.ncbi.nlm.nih.gov/articles/PMC9442799/
- SCDAA Statement About Gene Therapy Approval – Sickle Cell Disease Association of America Inc. – https://www.sicklecelldisease.org/2023/12/08/scdaa-statement-about-gene-therapy-approval/
- How Increased Use of Gene Therapy Treatment for Sickle Cell Disease Could Affect the Federal Budget – https://www.cbo.gov/publication/61149
- Future Directions of Sickle Cell Disease Research: The NIH Perspective – https://pmc.ncbi.nlm.nih.gov/articles/PMC3374062/
